Dual Roles of miR-10a-5p and miR-10b-5p as Tumor Suppressors and Oncogenes in Diverse Cancers

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(1), P. 415 - 415

Published: Jan. 6, 2025

Cancer is a complex genetic disorder characterized by abnormalities in both coding and regulatory non-coding RNAs. microRNAs (miRNAs) are key RNAs that modulate cancer development, functioning as tumor suppressors oncogenes. miRNAs play critical roles progression, influencing processes such initiation, promotion, metastasis. They exert their effects targeting suppressor genes, thereby facilitating while also inhibiting oncogenes to prevent further disease advancement. The miR-10 family, particularly miR-10a-5p miR-10b-5p (miR-10a/b-5p), notably involved progression. Intriguingly, functions can differ across different cancers, sometimes promoting at other times suppressing growth depending on the type target genes. This review explores dual of miR-10a/b-5p tumor-suppressive (TSmiRs) or oncogenic (oncomiRs) various cancers examining molecular cellular mechanisms impact microenvironment. Furthermore, we discuss potential therapeutic targets, emphasizing miRNA-based strategies for treatment. insights discussed this aim advance our understanding miR-10a/b-5p’s biology application developing innovative therapies.

Language: Английский

---

Unraveling the complexities of colorectal cancer and its promising therapies – An updated review

International Immunopharmacology, Journal Year: 2024, Volume and Issue: 143, P. 113325 - 113325

Published: Oct. 14, 2024

Language: Английский

---

Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy

Cancer Letters, Journal Year: 2024, Volume and Issue: unknown, P. 217350 - 217350

Published: Nov. 1, 2024

Pancreatic cancer remains one of the most challenging malignancies to treat due its late-stage diagnosis, aggressive progression, and high resistance existing therapies. This review examines latest advancements in early detection, therapeutic strategies, with a focus on emerging biomarkers, tumor microenvironment (TME) modulation, integration artificial intelligence (AI) data analysis. We highlight promising including microRNAs (miRNAs) circulating DNA (ctDNA), that offer enhanced sensitivity specificity for early-stage diagnosis when combined multi-omics panels. A detailed analysis TME reveals how components such as cancer-associated fibroblasts (CAFs), immune cells, extracellular matrix (ECM) contribute therapy by creating immunosuppressive barriers. also discuss interventions target these components, aiming improve drug delivery overcome evasion. Furthermore, AI-driven analyses are explored their potential interpret complex data, enabling personalized treatment strategies real-time monitoring response. conclude identifying key areas future research, clinical validation regulatory frameworks AI applications, equitable access innovative comprehensive approach underscores need integrated, outcomes pancreatic cancer.

Language: Английский

---

Oral Cancer: Recent Breakthroughs in Pathology and Therapeutic Approaches

Oral Oncology Reports, Journal Year: 2024, Volume and Issue: unknown, P. 100678 - 100678

Published: Oct. 1, 2024

Language: Английский

---

The adipokines in oral cancer pathogenesis and its potential as a new therapeutic approach

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: March 8, 2025

Language: Английский

---

Exosomes in Precision Oncology and Beyond: From Bench to Bedside in Diagnostics and Therapeutics

Cancers, Journal Year: 2025, Volume and Issue: 17(6), P. 940 - 940

Published: March 10, 2025

Exosomes have emerged as pivotal players in precision oncology, offering innovative solutions to longstanding challenges such metastasis, therapeutic resistance, and immune evasion. These nanoscale extracellular vesicles facilitate intercellular communication by transferring bioactive molecules that mirror the biological state of their parent cells, positioning them transformative tools for cancer diagnostics therapeutics. Recent advancements exosome engineering, artificial intelligence (AI)-driven analytics, isolation technologies are breaking barriers scalability, reproducibility, clinical application. Bioengineered exosomes being leveraged CRISPR-Cas9 delivery, while AI models enhancing biomarker discovery liquid biopsy accuracy. Despite these advancements, key obstacles heterogeneity populations lack standardized protocols persist. This review synthesizes pioneering research on biology, molecular translation, emphasizing dual roles both mediators tumor progression intervention. It also explores emerging areas, including microbiome–exosome interactions integration machine learning exosome-based medicine. By bridging innovation with translational strategies, this work charts a forward-looking path integrating into next-generation care, setting it apart comprehensive guide overcoming technological hurdles rapidly evolving field.

Language: Английский

---

Extracellular vesicles in cancer´s communication: messages we can read and how to answer

Molecular Cancer, Journal Year: 2025, Volume and Issue: 24(1)

Published: March 19, 2025

Abstract Extracellular vesicles (EVs) are emerging as critical mediators of intercellular communication in the tumor microenvironment (TME), profoundly influencing cancer progression. These nano-sized vesicles, released by both and stromal cells, carry a diverse cargo proteins, nucleic acids, lipids, reflecting dynamic cellular landscape mediating intricate interactions between cells. This review provides comprehensive overview biogenesis, composition, functional roles EVs cancer, highlighting their significance basic research clinical applications. We discuss how cells manipulate EV biogenesis pathways to produce enriched with pro-tumorigenic molecules, explore specific contributions key hallmarks such angiogenesis, metastasis, immune evasion, emphasizing role shaping TME driving therapeutic resistance. Concurrently, we submit recent knowledge on can serve valuable source biomarkers for minimally invasive liquid biopsies, its potential, particularly targeted drug delivery vehicles immunomodulatory agents, showcasing promise enhancing efficacy safety treatments. By deciphering messages carried EVs, gain deeper understanding biology develop more effective strategies early detection, therapy, immunotherapy, paving way new era personalized precise medicine potential significantly improve patient outcomes.

Language: Английский

---

CircNF1 modulates the progression and immune evasion of esophageal squamous cell carcinoma through dual regulation of PD-L1

Cellular & Molecular Biology Letters, Journal Year: 2025, Volume and Issue: 30(1)

Published: March 29, 2025

Abstract Background Tumor immune escape is a pivotal gateway for esophageal squamous cell carcinoma (ESCC) development. Immune checkpoint-blocking therapies, represented by programmed death receptor-1/ligand 1 (PD-1/PD-L1) inhibitors, have achieved remarkable breakthroughs in ESCC treatment. However, not all patients with receive satisfactory clinical benefit. Therefore, identifying novel biomarkers predicting the efficacy of immunotherapy great importance. Methods CircNF1 was screened from circRNAs microarray, and its expression measured droplet digital polymerase chain reaction (ddPCR) quantitative reverse transcriptase (qRT-PCR) assays tissues serum. Functional experiments were conducted to demonstrate role circNF1 proliferation, metastasis, tumor evasion. High-throughput RNA sequencing, chromatin immunoprecipitation (ChIP), co-immunoprecipitation (co-IP), isolation purification-mass spectrometry (ChIRP-MS) performed clarify underlying mechanisms circNF1-mediated progression. Results The upregulation closely associated response anti-PD-L1 immunotherapy. Functionally, promoted malignant phenotypes regulated CD8 + T-cell-mediated antitumor immunity. Mechanistically, drove IL-6-induced oncogenic activation JAK–STAT3 pathway, which stimulated p-STAT3 binding promoter regions PD-L1. Furthermore, physically interacted annexin A1 (ANXA1), blocking ANXA1 deubiquitination induced ubiquitin-specific protease 7 (USP7), resulting increased interaction between USP7 PD-L1 augmented stability. Conclusions Our findings provide insights into specific regulatory mechanism cells, offer new strategy synergizing therapy.

Language: Английский

---

Nanotherapeutic Formulations for the Delivery of Cancer Antiangiogenics

Molecular Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown

Published: April 4, 2025

Antiangiogenic medications for cancer treatment have generally failed in showing substantial benefits terms of prolonging life on their own; effects are noticeable only when combined with chemotherapy. Moreover, treatments based prolonged antiangiogenics administration demonstrated to be ineffective stopping tumor progression. In this scenario, nanotherapeutics can address certain issues linked existing antiangiogenic treatments. More specifically, they provide the ability target tumor's blood vessels enhance drug accumulation and manage release, ultimately decreasing undesired side effects. Additionally, enable multiple angiogenesis inhibitors at same time as Key reports field include design polymeric nanoparticles, inorganic vesicles, hydrogels loading substances like endostatin interleukin-12. Furthermore, nanoformulations been proposed efficiently control relevant pro-angiogenic pathways such VEGF, Tie2/Angiopoietin-1, HIF-1α/HIF-2α, TGF-β, providing powerful approaches block growth metastasis. article, we outline a selection that developed past ten years.

Language: Английский

---

Inhibition of miR-325 inhibits KIF20B expression and the colorectal cancer cells’ invasion & proliferation

BMC Cancer, Journal Year: 2025, Volume and Issue: 25(1)

Published: April 14, 2025

Language: Английский

---